AKT1 and hepatocellular carcinoma: The subsequent study applying small interfering RNA (siRNA) to target the GALK1 gene in the hepatocellular carcinoma (HCC) cell line supported GALK1 as a novel target for treating HCC and uncovered new posttranscriptional regulatory mechanisms that link the galactose metabolic pathway to protein expression of the PI3K/AKT pathway [50].